6004-52-0Relevant articles and documents
Preparation of secondary alkyl and benzylic zinc bromides using activated zinc metal deposited on titanium oxide
Stadtmuller,Greve,Lennick,Chair,Knochel
, p. 69 - 72 (1995)
Sodium dispersed on titanium oxide readily reduces zinc chloride leading to a highly active zinc powder which inserts into secondary alkyl and benzylic bromides under mild conditions, producing the corresponding zinc reagents in high yields. Compared to zinc dust, this activated zinc allows the preparation of secondary benzylic zinc bromides with significantly less Wurtz-coupling products.
A ketone the synthetic method of the compound of (by machine translation)
-
Paragraph 0030-0032, (2017/01/05)
The invention discloses a method for the synthesis of ketone compound, the aldehyde compound and cyclanes mixed or dissolved in organic solvent, in the microwave radiation and presence of radical initiator under the condition of the 140 [...] 180 °C reaction to obtain the target product ketone compound, in the synthesis method of the reaction equation: , Wherein R 1 is phenyl or substituted phenyl, substituted phenyl benzene ring substituted the base is the fluorine, chloro, bromo, methyl, methoxy, trifluoromethyl or hydroxy in one or more of, the position of the substituent on the benzene ring is ortho, meta or para position, as n the 1 [...] 4 integer between the, free-radical initiator is benzoyl peroxide, di-tert-butyl peroxide, or cumyl peroxide, organic solvent as the alkane or benzene. The invention discloses method for the synthesis of the raw material is cheap and easy to obtain, good atom economy, wide range of the application of substrates, and the like, is suitable for industrial production. (by machine translation)
QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS
-
Page/Page column 20, (2011/08/02)
The invention provides named compounds of formula (I), wherein R4 is a N-substituted quinuclidine (I) pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions. Their use in therapy for’ the treatment of conditions mediated by M3 muscarinic receptors, such as chronic obstructive pulmonary disease is also disclosed.